Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (827)	1/4/1999 8:18:00 PM
From: twt	Read Replies (2) \| Respond to of 2539

Anthony, thanks for all the information. A few more upgrades won't hurt either :-) If we can cross $50 I think the upside is much higher. Will see. Cheers.

To: Anthony Wong who wrote (827)	1/5/1999 8:31:00 AM
From: jopawa	Respond to of 2539

Monday January 4, 3:39 pm Eastern Time Monsanto looks to launch of new aspirin drug ORLANDO, Florida, Jan 4 (Reuters) - A senior official of agro-chemical group Monsanto Co. (NYSE:MTC - news) said Monday it is looking forward to the successful launch of its new aspirin replacement drug in 1999. Robert Fraley, co-president of the Agriculture Sector of Monsanto, told Reuters in an interview that the approval of celebrex by the Food and Drug Administration last Dec. 31 was ''a focal point'' for Monsanto this year. ''It should be a very exciting product for Monsanto,'' he said, adding that the studies he has seen on the new medication indicate it will be a, ''real blockbuster for 1999 and beyond.'' He said the drug was, ''going to be an aspirin replacement that has the benefits of pain relief without the side effects of producing ulcers.'' Monsanto and drug group Pfizer Inc. (NYSE:PFE - news) are partners in the launch of the new drug.

To: Anthony Wong who wrote (827)	1/5/1999 8:36:00 AM
From: jopawa	Respond to of 2539

More agri-bio news. John Monday January 4, 6:48 pm Eastern Time Monsanto may be step closer to closing Delta buy By Emily Kaiser CHICAGO, Jan 4 (Reuters) - Life sciences firm Monsanto Co. (NYSE:MTC - news) may have taken a giant step closer to government approval of its deal to acquire cotton seed maker Delta & Pine Land Co. (NYSE:DLP - news) with its decision to auction off its cotton seed subsidiary, analysts said on Monday. A Monsanto official told Reuters on Monday the company plans to sell its wholly owned subsidiary Stoneville Pedigree Seed Co. in early 1999. Robert Fraley, co-president of Monsanto's Agriculture Sector, said the company ''will initiate an auction process for the sale of Stoneville.'' Monsanto officials did not say how much they hope to earn from the sale of Stoneville. Stoneville is the second largest U.S. cotton seed breeder behind Delta & Pine Land. Analysts have long speculated that Monsanto would be required to divest some of its cotton assets before the U.S. Justice Department would approve its planned acquisition of Delta, which was first announced in May. The Justice Department in June requested more details on the deal. A Monsanto spokeswoman declined to speculate on whether selling Stoneville would bring the company closer to Justice Department approval. ''They fact that they're going to sell it (Stoneville) is not surprising because that is the only way they were going to be able to buy Delta & Pine Land,'' said George Dahlman, agribusiness analyst with Piper Jaffray. Dahlman said the most likely candidate to buy Stoneville is Rhone-Poulenc SA , the French life sciences firm. Other bidders will likely include Dow Chemical Co. (NYSE:DOW - news), which owns seed company Mycogen Corp., and Hoechst Schering AgrEvo GmbH (quote from Yahoo! UK & Ireland: HOEG.F)(quote from Yahoo! UK & Ireland: SCHG.F), Dahlman said. A spokeswoman for Dow's agricultural unit Dow AgroSciences could not be reached. Calls to AgrEvo's North American offices in Regina, Canada, were not immediately returned, and Rhone-Poulenc could not be reached. Another analyst who declined to be named said the sale of Stoneville would also help Monsanto pay for an estimated $6 billion in acquisitions it announced in 1998. The company has said it will divest some assets to help pay for the purchases. "Monsanto wants to raise some money," the analyst said." Shares of Monsanto closed up 7/16 at 47-15/16.